Last updated on May 2020

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy

Brief description of study

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

Clinical Study Identifier: NCT02864251

Find a site near you

Start Over

Local Institution

Yokohama-shi, Japan
  Connect »

Local Institution

Yokohama, Japan
  Connect »